Luteolin alters MUC1 extracellular domain, sT antigen, ADAM-17, IL-8, IL-10 and NF-[kappa]B expression in Helicobacter pylori-infected gastric cancer CRL-1739 cells: A preliminary study

Luteolin is a natural flavonoid possessing certain beneficial pharmacological properties, including anti-oxidant, anti-inflammatory, anti-microbial and anti-cancer properties. The majority of types of gastric cancer with chronic gastritis are caused by infection with Helicobacter pylori (H. pylori)....

Full description

Saved in:
Bibliographic Details
Published in:Biomedical reports 2021-02, Vol.14 (2), p.1
Main Authors: Radziejewska, Iwona, Borzym-Kluczyk, Malgorzata, Leszczynska, Katarzyna
Format: Article
Language:English
Subjects:
Antigens
Bioflavonoids
Cancer
Care and treatment
Enzyme-linked immunosorbent assay
Flavones
Flavonoids
Health aspects
Helicobacter infections
Helicobacter pylori
Infection
Mucins
Oncology, Experimental
Pharmaceutical industry
RNA
Stomach cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Luteolin is a natural flavonoid possessing certain beneficial pharmacological properties, including anti-oxidant, anti-inflammatory, anti-microbial and anti-cancer properties. The majority of types of gastric cancer with chronic gastritis are caused by infection with Helicobacter pylori (H. pylori). The present study evaluated the effect of luteolin on a number of selected factors that are potentially involved in gastric cancer development. The study was performed using gastric cancer CRL-1739 cells treated with 30 [micro]M luteolin and H. pylori alone or combined. ELISA and reverse transcription PCR were used to assess the expression levels of MUC1, GalNAc[alpha]-R (Tn antigen) and NeuAc[alpha]2-3Gal[beta]1-3GalNAc-R (sT antigen), ADAM-17, IL-8, IL-10 and NF-[kappa]B. H. pylori and luteolin independently and in combination significantly reduced the expression levels of the extracellular domain of MUC1 in gastric cancer cells compared with the untreated control cells. ADAM-17 expression was reduced by treatment with the pathogen and luteolin. Additionally, both factors reduced sT antigen expression. Treatment with 30 [less than or equal to]M luteolin significantly induced IL-8 expression at the mRNA and protein level, and the mRNA expression levels of IL-10 and NF-[kappa]B compared with the control. Both H. pylori and luteolin induced IL-8 protein expression. The present preliminary results suggest that luteolin may be used to treat patients with gastric cancer.
ISSN:2049-9434
DOI:10.3892/br.2020.1395